CA2182183A1 - Traitement de pathologies dependant des oestrogenes ovariens - Google Patents

Traitement de pathologies dependant des oestrogenes ovariens

Info

Publication number
CA2182183A1
CA2182183A1 CA002182183A CA2182183A CA2182183A1 CA 2182183 A1 CA2182183 A1 CA 2182183A1 CA 002182183 A CA002182183 A CA 002182183A CA 2182183 A CA2182183 A CA 2182183A CA 2182183 A1 CA2182183 A1 CA 2182183A1
Authority
CA
Canada
Prior art keywords
treatment
estrogen dependent
ovarian estrogen
dependent conditions
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002182183A
Other languages
English (en)
Other versions
CA2182183C (fr
Inventor
Gary D. Hodgen
Robert F. Williams
Daniel Grow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eastern Virginia Medical School
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2182183A1 publication Critical patent/CA2182183A1/fr
Application granted granted Critical
Publication of CA2182183C publication Critical patent/CA2182183C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un procédé pour traiter une pathologie dépendant des oestrogènes ovariens, telle que l'endométriose, les fibromyomes utérins, le syndrome prémenstruel ou les hémorragies utérines dysfonctionnelles, comprend l'administration d'un analogue de la gonadolibérine et l'administration d'une anti-progestérone, en vue de constituer un procédé thérapeutique pour un traitement à long terme sans perte rapide de densification osseuse, comme c'est le cas avec des analogues de GnRH seuls.
CA002182183A 1994-02-04 1995-02-02 Traitement de pathologies dependant des oestrogenes ovariens Expired - Fee Related CA2182183C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/191,631 US5681817A (en) 1994-02-04 1994-02-04 Treatment of ovarian estrogen dependent conditions
US08/191,631 1994-02-04
PCT/US1995/001479 WO1995020972A1 (fr) 1994-02-04 1995-02-02 Traitement de pathologies dependant des ×strogenes ovariens

Publications (2)

Publication Number Publication Date
CA2182183A1 true CA2182183A1 (fr) 1995-08-10
CA2182183C CA2182183C (fr) 2003-09-16

Family

ID=22706258

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002182183A Expired - Fee Related CA2182183C (fr) 1994-02-04 1995-02-02 Traitement de pathologies dependant des oestrogenes ovariens

Country Status (29)

Country Link
US (1) US5681817A (fr)
EP (1) EP0785792B1 (fr)
JP (1) JP3130048B2 (fr)
KR (1) KR970700507A (fr)
CN (1) CN1144486A (fr)
AP (1) AP724A (fr)
AT (1) ATE179610T1 (fr)
AU (1) AU689229B2 (fr)
BG (1) BG62238B1 (fr)
BR (1) BR9506606A (fr)
CA (1) CA2182183C (fr)
CZ (1) CZ291709B6 (fr)
DE (1) DE69509544T2 (fr)
DK (1) DK0785792T3 (fr)
ES (1) ES2132645T3 (fr)
FI (1) FI963036L (fr)
GR (1) GR3030164T3 (fr)
HU (1) HUT74622A (fr)
LT (1) LT4182B (fr)
LV (1) LV11782B (fr)
MD (1) MD1432C2 (fr)
NZ (1) NZ281441A (fr)
OA (1) OA10777A (fr)
PL (1) PL178273B1 (fr)
RO (1) RO117420B1 (fr)
RU (1) RU2110274C1 (fr)
SK (1) SK96296A3 (fr)
TJ (1) TJ242B (fr)
WO (1) WO1995020972A1 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996003138A1 (fr) * 1994-07-22 1996-02-08 The Medical College Of Hampton Roads Procede pour assurer une secretion tonique d'oestrogene ovarien dans des regimes therapeutiques de longue duree
US5780435A (en) * 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
US6274573B1 (en) 1997-10-17 2001-08-14 Mochida Pharmaceutical Co., Ltd. Method of treatment for uterine leiomyoma
US6703367B1 (en) 1999-04-27 2004-03-09 Praecis Pharmaceuticals Inc. Methods for treating hot flashes and gynaecomastia
US6399593B1 (en) 1999-05-04 2002-06-04 Wyeth Cyclic regimens using cyclic urea and cyclic amide derivatives
US6444668B1 (en) 1999-05-04 2002-09-03 Wyeth Combination regimens using progesterone receptor modulators
US6358948B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
US6462032B1 (en) 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
US6329416B1 (en) 1999-05-04 2001-12-11 American Home Products Corporation Combination regimens using 3,3-substituted indoline derivatives
US6391907B1 (en) * 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6306851B1 (en) 1999-05-04 2001-10-23 American Home Products Corporation Cyclocarbamate and cyclic amide derivatives
US6407101B1 (en) 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6380178B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Cyclic regimens using cyclocarbamate and cyclic amide derivatives
US6319912B1 (en) 1999-05-04 2001-11-20 American Home Products Corporation Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides
US6369056B1 (en) 1999-05-04 2002-04-09 American Home Products Corporation Cyclic urea and cyclic amide derivatives
US6339098B1 (en) 1999-05-04 2002-01-15 American Home Products Corporation 2,1-benzisothiazoline 2,2-dioxides
US6355648B1 (en) * 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6358947B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Tetracyclic progesterone receptor modulator compounds and methods
US6417214B1 (en) 1999-05-04 2002-07-09 Wyeth 3,3-substituted indoline derivatives
US6498154B1 (en) 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
US6423699B1 (en) 1999-05-04 2002-07-23 American Home Products Corporation Combination therapies using benzimidazolones
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6380235B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Benzimidazolones and analogues
US8193252B1 (en) 1999-08-31 2012-06-05 Bayer Pharma AG Mesoprogestins (progesterone receptor modulators) for the treatment and prevention of benign hormone dependent gynecological disorders
ES2295050T3 (es) * 1999-08-31 2008-04-16 Bayer Schering Pharma Aktiengesellschaft Mesoprogestinas para el tratamiento y la prevencion de trastornos ginecologicos benignos dependientes de hormonas.
UA73119C2 (en) * 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
AU2001295359A1 (en) * 2000-10-30 2002-05-15 University Of Zurich GnRH analogues for treatment of urinary incontinence
US6958142B2 (en) * 2002-08-02 2005-10-25 Balance Pharmaceuticals, Inc. Nasal spray formulation and method
US6960337B2 (en) * 2002-08-02 2005-11-01 Balance Pharmaceuticals, Inc. Methods and compositions for treating benign gynecological disorders
US7029657B2 (en) * 2002-08-02 2006-04-18 Balance Pharmaceuticals, Inc. Nasal spray steroid formulation and method
GB0302572D0 (en) 2003-02-05 2003-03-12 Astrazeneca Ab Method of treatment
EP1865935B1 (fr) * 2005-02-17 2011-06-08 Hadasit Medical Research Services and Development Ltd. Bisphosphonates pour le traitement de l'endometriose
US20060251581A1 (en) * 2005-05-09 2006-11-09 Mcintyre Jon T Method for treatment of uterine fibroid tumors
US7862552B2 (en) 2005-05-09 2011-01-04 Boston Scientific Scimed, Inc. Medical devices for treating urological and uterine conditions
TWI455716B (zh) * 2006-10-24 2014-10-11 Repros Therapeutics Inc 選擇性黃體激素受體調節劑用於製造治療雌激素依賴性病症之藥物的用途
MY150763A (en) * 2006-10-24 2014-02-28 Repros Therapeutics Inc Compositions and methods for suppressing endometrial proliferation
WO2008144143A1 (fr) * 2007-05-14 2008-11-27 Drugtech Corporation Traitement de l'endométriose
US20110208118A1 (en) * 2007-09-20 2011-08-25 Bio-Pro Medical Ltd. Compositions and means for treating uterine leiomyomata, leiomyoma, myoma, uterine fibroids, endometriosis, adenomyosis and related disorders by mifepristone
RU2359684C1 (ru) * 2008-01-23 2009-06-27 Закрытое акционерное общество "СКАЙ ЛТД" Способ лечения эндометриоза
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
EP3560555A1 (fr) 2018-04-26 2019-10-30 LifeArc Composition pour traiter une ou plusieurs maladies liées aux strogènes

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA8231B (en) 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
US4780461A (en) 1983-06-15 1988-10-25 Schering Aktiengesellschaft 13α-alkyl-gonanes, their production, and pharmaceutical preparations containing same
DE3347126A1 (de) 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen 11ss-aryl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
DE19975054I2 (de) 1987-08-08 2000-04-13 Akzo Nobel Nv Kontrazeptives Implantat
DE3744054A1 (de) 1987-12-21 1989-06-29 Schering Ag Verwendung von antigestagenen zur herstellung von arzneimitteln
DE3921059A1 (de) 1989-06-23 1991-01-10 Schering Ag 11(beta)-aryl-4-estrene, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel
EP0472725B1 (fr) 1990-03-16 1997-05-21 Applied Research Systems Ars Holding N.V. Traitement de la polykystose ovarienne
US6827050B2 (en) 2001-12-21 2004-12-07 Caterpillar Inc Fluid control valve actuating system
US7283632B2 (en) 2003-09-09 2007-10-16 The Boeing Company Unauthorized access embedded software protection system

Also Published As

Publication number Publication date
BR9506606A (pt) 1997-09-09
CN1144486A (zh) 1997-03-05
LV11782A (lv) 1997-06-20
TJ242B (en) 1999-11-24
FI963036A0 (fi) 1996-08-01
FI963036A7 (fi) 1996-08-01
ES2132645T3 (es) 1999-08-16
SK96296A3 (en) 1997-07-09
OA10777A (en) 2002-12-23
MD1432C2 (ro) 2000-09-30
AU689229B2 (en) 1998-03-26
LT4182B (en) 1997-06-25
DE69509544D1 (de) 1999-06-10
DK0785792T3 (da) 1999-10-18
EP0785792B1 (fr) 1999-05-06
DE69509544T2 (de) 1999-09-02
RO117420B1 (ro) 2002-03-29
BG62238B1 (bg) 1999-06-30
PL178273B1 (pl) 2000-03-31
BG100766A (bg) 1997-06-30
GR3030164T3 (en) 1999-08-31
MD1432B2 (en) 2000-03-31
CA2182183C (fr) 2003-09-16
WO1995020972A1 (fr) 1995-08-10
AP9600840A0 (en) 1996-07-31
EP0785792A4 (fr) 1997-07-30
US5681817A (en) 1997-10-28
CZ291709B6 (cs) 2003-05-14
EP0785792A1 (fr) 1997-07-30
JPH09508418A (ja) 1997-08-26
FI963036L (fi) 1996-08-01
NZ281441A (en) 1999-09-29
RU2110274C1 (ru) 1998-05-10
ATE179610T1 (de) 1999-05-15
LT96133A (en) 1997-01-27
LV11782B (en) 1997-12-20
AU1838695A (en) 1995-08-21
CZ210396A3 (en) 1997-05-14
JP3130048B2 (ja) 2001-01-31
PL315792A1 (en) 1996-12-09
AP724A (en) 1999-01-18
KR970700507A (ko) 1997-02-12
HUT74622A (en) 1997-01-28
HU9601969D0 (en) 1996-09-30

Similar Documents

Publication Publication Date Title
GR3030164T3 (en) Treatment of ovarian estrogen dependent conditions
IL124459A0 (en) Antagonists of gonadotropin releasing hormone
MX9804850A (es) Antagonistas de hormona liberadora de gonadotropina.
NZ325060A (en) Non peptide indole derivative and their use as antagonists of gonadotropin releasing hormone
DE69511379D1 (en) Immunogens gegen gonadotropin releasing hormone
PL327182A1 (en) Method of preventing conception among female mammals through combined application of gestagen and oestrogen and combination of active agent therefor
NZ221991A (en) Device for the transdermal delivery of progesterone, estradiol esters and mixtures thereof; and compositions therefor
FI970260L (fi) Progesteroniantagonisti ja gestageeni endometrioosin ja leiomyomata uterin hoitamiseksi
IL108958A0 (en) Sulfonate and carbamate derivatives of 3-aroylbenzo (b) thiophenes
UA37259C2 (uk) Активна речовина для одержання лікарських засобів при лікуванні дисфункціональних маткових кровотеч
AU8727798A (en) Gonadotropin releasing hormone antagonist
CA2137595A1 (fr) Traitement pour les conditions hormonodependantes
HUP9702477A3 (en) New polymorphous form of doxazosin-mesylate (form iii), process for it's preparation and pharmaceutical compositions containing the same
WO2000021511A3 (fr) Acetate de medroxyprogesterone administre par voie sous-cutanee en vue du traitement de la menopause et de l'endometriose
HUP9702479A3 (en) New polymorphous form of doxazosin-mesylate (form ii.), process for it's preparation and pharmaceutical compositions containing the same
UA41351C2 (uk) Спосіб контрацепції та набір таблеток
CA2248841A1 (fr) Combinaison sequentielle oestrogene/antagoniste de la progesterone s'utilisant en therapie hormonale de substitution
CA2054686A1 (fr) Traitement du syndrome des ovaires polykystiques
NZ330603A (en) Hyaluronic acid derivatives used as cervical ripening agents
PT1091750E (pt) Composição farmacêutica cerebroespinal e vascular e processo para a sua preparação
CA2056364A1 (fr) Compositions et methodes pour la contraception
CA2005420A1 (fr) Antagonistes competitifs de la gonadoliberine
ZA933320B (en) Contraception method using competitive progesterone antagonists and novel compounds usuful therein
Lee et al. Stress Analysis of Dental Implant System Using Homogenization Technique
GR3017136T3 (en) 2,19-Methyleneoxy and 2,19-methylenethio bridged steroids as aromatase and 19-hydroxylase inhibitors.

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed
MKLA Lapsed

Effective date: 20060202